898 results on '"Boguniewicz, Mark"'
Search Results
2. Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities
3. Current and Emerging Biologics for Atopic Dermatitis
4. Atopic Dermatitis (Eczema) Guidelines 2023: Highlights
5. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology
6. Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus
7. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review
8. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
9. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
10. CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity
11. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
12. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
13. The role of Janus kinase signaling in the pathology of atopic dermatitis
14. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
15. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
16. Adverse reactions to antibiotics : is the patient really allergic?
17. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
18. Atopic Dermatitis Yardstick update
19. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin
20. List Of Contributors
21. Atopic and Contact Dermatitis
22. Use of Vaccines in Patients Receiving Dupilumab, A Systematic Review and Expert Delphi Consensus Recommendation: A position paper of the American College of Allergy, Asthma and Immunology
23. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
24. Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
25. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
26. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE
27. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
28. Contributors
29. Atopic Dermatitis and Allergic Contact Dermatitis
30. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
31. Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis.
32. The infectious complications of atopic dermatitis
33. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial
34. Biologics for Atopic Dermatitis
35. 563 - Dupilumab improves skin lipid composition in atopic dermatitis irrespective of patient filaggrin (FLG) mutation status
36. Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Disease Severity And Age Subgroups In The Treatment Of Adults And Children Down To 2 Years Of Age With Moderate To Severe Atopic Dermatitis
37. 548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities
38. Dupilumab Consistently Reduces CCL-17 (TARC) in Patients with Atopic Dermatitis Across All Age Groups
39. 505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
40. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
41. Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
42. Cutaneous Ceramide Synthase 1 (CERS1) Gene Expression is a Biomarker of Staphylococcus aureus Abundance and Severity of Atopic Dermatitis
43. Topical Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
44. Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
45. Systemic Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
46. 562 - Dupilumab treatment provides long-term improvement in itch in pediatric patients with moderate-to-severe atopic dermatitis over 1 year
47. Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities
48. Study of the Atopic March: Development of Atopic Comorbidities
49. Tapinarof Validates the Aryl Hydrocarbon Receptor as a Therapeutic Target: A Clinical Review
50. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.